Answers are grounded in this paper and cite their sources.
Retrospective cohort study demonstrates reduced non-drug healthcare costs in older adults taking tirzepatide, suggesting substantial near-term cost offsets.
AIMS: Compare healthcare cost trends among older adults with obesity or overweight treated with tirzepatide versus no treatment. MATERIALS AND METHODS: Retrospective cohort study using real-world data from US Komodo Research Dataset, 8 November 2022 to 30 September 2025. Adults > 55 years with obesity, or overweight with ≥ 1 weight-related comorbidity, without T2 diabetes who initiated tirzepatide for weight management were compared with propensity score-matched individuals who did not receive any incretin-based therapies. Changes in all-cause healthcare costs (excluding tirzepatide; per-person-per-month) between cohorts were assessed at 3-6, 6-12 and 12-18 months using a difference in differences (DiD) framework. Informative censoring and differential follow-up were addressed with inverse-probability-of-censoring-weights and pairwise censoring. RESULTS: Each cohort comprised 15843 individuals. Healthcare cost DiD estimates (95% CI) for the tirzepatide versus control cohorts were -$145 (-266, -25; 12.3% reduction; p = 0.022) during 6-12 months and -$319 (-544, -94; 25.4% reduction; p = 0.015) during 12-18 months; using pairwise censoring, estimates were -$181 (-319, -43; p = 0.021) and -$607 (-1007, -207; p = 0.023), respectively. Cost offsets with tirzepatide were driven by higher medical costs in controls during 12-18 months (-$211 [-$407, -$15]; p = 0.065) and fewer inpatient/emergency department visits with tirzepatide versus controls; incidence rate ratio (95% CI) 0.69 (0.50, 0.94; p = 0.021) during 12-18 months. CONCLUSIONS: Monthly cost offsets for persistent tirzepatide users versus untreated individuals grew over time, offsetting $319 (ranging from $94 to $544) tirzepatide costs by 12-18 months. These results have implications for the $195 monthly net Medicare cost for the Bridge programme, suggesting tirzepatide may generate near-term cost savings in an older population that stays on treatment.
No takes yet. Share an insight, caveat, or question.
Upadhyay et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: